BitFrontier Capital Holdings to Acquire EVERMIND Beverage Platform
ByAinvest
Monday, Aug 4, 2025 7:17 am ET1min read
KDP--
EVERMIND(TM) is designed as a creamy, plant-based protein shake that delivers both short- and long-term brain health benefits. The platform includes six flagship proprietary nootropic and adaptogenic formulations, an R&D pipeline, academic research, registered trademarks, and commercialization-ready branding. The acquisition is structured to materially strengthen BFCH's balance sheet by adding structured, IP-backed assets and aligning with the company's OTCQB uplisting strategy [1].
The acquisition also aims to eliminate over $2 million in toxic convertible debt, reducing total liabilities to under $94,000. This move supports BFCH's broader capital markets strategy and positions the company for future growth. Dr. Jordan Balencic, CEO of BFCH, noted that the acquisition is not just about a beverage asset but a platform that is built to scale, spin off, and anchor the broader wellness ecosystem [1].
The functional beverage space has seen growing institutional interest, with recent transactions such as Keurig Dr Pepper’s $300M investment in Poppi, Coca-Cola’s majority stake in Health-Ade, and Unilever’s acquisition of Liquid I.V. validating this trend [1]. EVERMIND(TM) positions BFCH to participate in this momentum with a differentiated, brain-first platform.
The transaction is expected to close within 60 to 90 days, subject to standard confirmatory due diligence and final documentation. Upon completion, EVERMIND(TM) will operate as a wholly-owned subsidiary of EVERMIND Labs, with future spin-off optionality [1].
References:
[1] https://www.finanzen.at/nachrichten/aktien/eqs-news-bfch-signs-binding-loi-to-acquire-evermindtm-beverage-a-science-supported-cognitive-health-platform-1034978210
[2] https://www.marketscreener.com/news/bfch-signs-binding-loi-to-acquire-evermind-tm-beverage-a-science-supported-cognitive-health-platf-ce7c5edadd81f222
KO--
UL--
BitFrontier Capital Holdings (BFCH) has signed a binding Letter of Intent to acquire ERApeutics, LLC, the developer of EVERMIND(TM) - a physician-formulated functional beverage platform for cognitive health. The transaction is structured as a $4,000,000 equity acquisition, with BFCH issuing 400,000,000 restricted common shares at a fixed price of $0.01 per share. The EVERMIND(TM) platform includes six flagship proprietary nootropic and adaptogenic formulations, an R&D pipeline, academic research, registered trademarks, and commercialization-ready branding.
BitFrontier Capital Holdings, Inc. (OTC: BFCH), doing business as EVERMIND Holdings, Inc., has signed a binding Letter of Intent (LOI) to acquire ERApeutics, LLC, the developer of EVERMIND(TM) - a physician-formulated functional beverage platform for cognitive health. The transaction, valued at $4,000,000, involves the issuance of 400,000,000 restricted common shares at a fixed price of $0.01 per share [1].EVERMIND(TM) is designed as a creamy, plant-based protein shake that delivers both short- and long-term brain health benefits. The platform includes six flagship proprietary nootropic and adaptogenic formulations, an R&D pipeline, academic research, registered trademarks, and commercialization-ready branding. The acquisition is structured to materially strengthen BFCH's balance sheet by adding structured, IP-backed assets and aligning with the company's OTCQB uplisting strategy [1].
The acquisition also aims to eliminate over $2 million in toxic convertible debt, reducing total liabilities to under $94,000. This move supports BFCH's broader capital markets strategy and positions the company for future growth. Dr. Jordan Balencic, CEO of BFCH, noted that the acquisition is not just about a beverage asset but a platform that is built to scale, spin off, and anchor the broader wellness ecosystem [1].
The functional beverage space has seen growing institutional interest, with recent transactions such as Keurig Dr Pepper’s $300M investment in Poppi, Coca-Cola’s majority stake in Health-Ade, and Unilever’s acquisition of Liquid I.V. validating this trend [1]. EVERMIND(TM) positions BFCH to participate in this momentum with a differentiated, brain-first platform.
The transaction is expected to close within 60 to 90 days, subject to standard confirmatory due diligence and final documentation. Upon completion, EVERMIND(TM) will operate as a wholly-owned subsidiary of EVERMIND Labs, with future spin-off optionality [1].
References:
[1] https://www.finanzen.at/nachrichten/aktien/eqs-news-bfch-signs-binding-loi-to-acquire-evermindtm-beverage-a-science-supported-cognitive-health-platform-1034978210
[2] https://www.marketscreener.com/news/bfch-signs-binding-loi-to-acquire-evermind-tm-beverage-a-science-supported-cognitive-health-platf-ce7c5edadd81f222
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet